Want to join the conversation?
In 1Q16, $CMA took actions to reduce cost by renegotiating vendor contracts, reducing real estate, and rationalizing some operations. To achieve double-digit ROE, company has been undertaking a review of its expense and revenue base, and to help in these efforts it has engaged Boston Consulting Group.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.